The trial has already recruited 240-patients.
The only aspect of the trial that stopped for a period of time was the enrollment of additional new patients beyond the 33 patients who were already enrolled and receiving ongoing treatment.
Northwest said that in Phase I studies, DCVax have showed positive results with a number of patients living more than 3 years.
Principal investigator of the study Linda Liau said after more than 10 years of development, DCVax is poised to make a real difference in the future treatment of brain cancer.
"DCVax is at the forefront of personalized therapy, which offers great potential for improving patients’ outcomes," Liau said.